Regulatory Story
Go to market news section View chart   Print
Tissue Regenix Group PLC  -  TRX   

Tissue Regenix board changes

Released 11:21 30-Nov-2012

RNS Number : 4310S
Tissue Regenix Group PLC
30 November 2012



Tissue Regenix board changes


York - 30 November 2012 - Tissue Regenix Group plc ('Tissue Regenix'), the regenerative medical devices specialist has appointed Dr Alison Fielding, Chief Operating Officer at IP Group plc, as a non-executive director with immediate effect. Alan Aubrey has today stepped down as the IP Group plc representative on the board.


Dr Alison Fielding will work with the management team to continue Tissue Regenix's strategy to accelerate the development of a range of products based on its patented dCELL® technology.


John Samuel, Executive Chairman of Tissue Regenix stated: "We would like to thank Alan for his significant contribution to Tissue Regenix and we are delighted that Alison is joining the board. We are confident that her expertise and experience in the healthcare sector will help drive forward the development of Tissue Regenix.  She joins Tissue Regenix at an exciting time for the company with a number of treatments in clinical and pre-clinical trials. We have also established a subsidiary company in the United States to explore the market there for dCELL® regenerative medicine."


Dr Alison Fielding is Chief Operating Officer at IP Group plc, a leading UK intellectual property commercialisation company. Alison co-founded Techtran Group Ltd and was the Chief Operating Officer of Techtran, which was acquired by IP Group plc in January 2005. Previously, she spent five years at McKinsey & Co where she consulted the pharmaceutical and health care sectors. Alison has also worked as a development chemist for Zeneca, carrying out technical roles in the specialty chemicals and agrochemicals divisions.


Further Information:

Full Name:  Alison Margaret Fielding

Age:  48


List of Current Directorships and Partnerships:

Techtran Group Limited

Techtran Investments Limited

Techtran Services Limited

Techtran Limited

IP Group Plc

Care International UK


Amaethon Trustees Limited

Perachem Limited

Green Chemicals Plc

IP Industry Partners Limited

The Foundation for Social Entrepreneurs

Top Technology Ventures Limited

Fusion IP Plc

IP2IPO Limited

IP2IPO Services Limited

Getech Group Plc

Techtran Corporate Finance Limited


List of Previous Directorships and Partnerships:

COE Group plc

Amaethon Limited

Crysalin Limited

Pure Polymers Limited


Alison Fielding has confirmed that there is no further information to be disclosed in accordance with the requirements of Schedule Two paragraph (g) of the AIM rules.




For Further Information

Tissue Regenix Group plc:                                                           01904 435 176

Antony Odell

Ian Jefferson


Peel Hunt LLP (Nominated Adviser):                                      020 7418 8900

James Steel

Vijay Barathan


Newgate Communications:

Alistair Kellie                                                                                    07557 651840

Andrew Adie                                                                                    07970 256512

Martin Greig                                                                                     07584 221513



About Tissue Regenix

Tissue Regenix is a leading medical devices company in the field of regenerative medicine. The company's patented decellularisation ('dCELL®) technology removes DNA and other cellular material from animal and human tissue leaving an acellular tissue scaffold which is not rejected by the patient's body which can then be used to repair diseased or worn out body parts. The potential applications of this process are diverse and address many critical clinical needs such as vascular disease, heart valve replacement and knee repair.


Tissue Regenix was formed in 2006 when it was spun-out from the University of Leeds. The company commercialises academic research conducted by our partners around the World.


This information is provided by RNS
The company news service from the London Stock Exchange

London Stock Exchange plc is not responsible for and does not check content on this Website. Website users are responsible for checking content. Any news item (including any prospectus) which is addressed solely to the persons and countries specified therein should not be relied upon other than by such persons and/or outside the specified countries. Terms and conditions, including restrictions on use and distribution apply.


Tissue Regenix board changes - RNS